The shareholders of Mendus AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Extraordinary General Meeting (“EGM”) on Monday, 10.
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation.